Contact
Please use this form to send email to PR contact of this press release:
POP BIO and EuBiologics’ EuCorVac-19 COVID-19 vaccine hits target in Phase 3 trial
TO:
Jonathan R Smyth
POP Biotechnologies, Inc.
+1 315-220-0087